Stock Track | Bionano Genomics (BNGO) Soars 9.83% Pre-Market on Breakthrough Multiple Myeloma Study

Stock Track2025-04-08

Bionano Genomics (NASDAQ: BNGO) stock is experiencing a significant pre-market surge, jumping 9.83% as investors react to a groundbreaking study utilizing the company's optical genome mapping (OGM) technology.

The rally comes on the heels of an announcement regarding a new study published in The Journal of Molecular Diagnostics. The research, conducted at Lille University Hospital in France, describes an innovative method for analyzing multiple myeloma (MM) using Bionano's OGM technology, potentially overcoming longstanding challenges in the field.

Key findings from the study showcase OGM's ability to effectively analyze MM samples with as few as 0.5 million CD138-positive cells, half the typical requirement. The technology demonstrated 93% concordance with traditional FISH methods while uncovering 22 additional genetic variants. This breakthrough could streamline MM analysis, improve prognostic risk evaluation, and potentially expand the adoption of OGM in hematologic malignancy research. The positive implications for Bionano's technology in addressing unmet medical needs in blood cancer research appear to be driving investor enthusiasm in pre-market trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117867412?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-08 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117867412","market":"hk","top_or_hot":-1,"title":"Stock Track | Bionano Genomics (BNGO) Soars 9.83% Pre-Market on Breakthrough Multiple Myeloma Study","media":"Stock Track","content":"<p>Bionano Genomics (NASDAQ: BNGO) stock is experiencing a significant pre-market surge, jumping 9.83% as investors react to a groundbreaking study utilizing the company's optical genome mapping (OGM) technology.</p>\n\n<p>The rally comes on the heels of an announcement regarding a new study published in The Journal of Molecular Diagnostics. The research, conducted at Lille University Hospital in France, describes an innovative method for analyzing multiple myeloma (MM) using Bionano's OGM technology, potentially overcoming longstanding challenges in the field.</p>\n\n<p>Key findings from the study showcase OGM's ability to effectively analyze MM samples with as few as 0.5 million CD138-positive cells, half the typical requirement. The technology demonstrated 93% concordance with traditional FISH methods while uncovering 22 additional genetic variants. This breakthrough could streamline MM analysis, improve prognostic risk evaluation, and potentially expand the adoption of OGM in hematologic malignancy research. The positive implications for Bionano's technology in addressing unmet medical needs in blood cancer research appear to be driving investor enthusiasm in pre-market trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bionano Genomics (BNGO) Soars 9.83% Pre-Market on Breakthrough Multiple Myeloma Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bionano Genomics (BNGO) Soars 9.83% Pre-Market on Breakthrough Multiple Myeloma Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-04-08 20:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bionano Genomics (NASDAQ: BNGO) stock is experiencing a significant pre-market surge, jumping 9.83% as investors react to a groundbreaking study utilizing the company's optical genome mapping (OGM) technology.</p>\n\n<p>The rally comes on the heels of an announcement regarding a new study published in The Journal of Molecular Diagnostics. The research, conducted at Lille University Hospital in France, describes an innovative method for analyzing multiple myeloma (MM) using Bionano's OGM technology, potentially overcoming longstanding challenges in the field.</p>\n\n<p>Key findings from the study showcase OGM's ability to effectively analyze MM samples with as few as 0.5 million CD138-positive cells, half the typical requirement. The technology demonstrated 93% concordance with traditional FISH methods while uncovering 22 additional genetic variants. This breakthrough could streamline MM analysis, improve prognostic risk evaluation, and potentially expand the adoption of OGM in hematologic malignancy research. The positive implications for Bionano's technology in addressing unmet medical needs in blood cancer research appear to be driving investor enthusiasm in pre-market trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"","article_id":"1117867412","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117867412","pubTimestamp":1744117005,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Bionano Genomics  stock is experiencing a significant pre-market surge, jumping 9.83% as investors react to a groundbreaking study utilizing the company's optical genome mapping  technology.The rally comes on the heels of an announcement regarding a new study published in The Journal of Molecular Diagnostics. The research, conducted at Lille University Hospital in France, describes an innovative method for analyzing multiple myeloma  using Bionano's OGM technology, potentially overcoming longsta","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"股票跟踪Bionano Genomics(BNGO)因突破性多发性骨髓瘤研究而盘前飙升9.83%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":1},"content_text":"Bionano Genomics (NASDAQ: BNGO) stock is experiencing a significant pre-market surge, jumping 9.83% as investors react to a groundbreaking study utilizing the company's optical genome mapping (OGM) technology.\nThe rally comes on the heels of an announcement regarding a new study published in The Journal of Molecular Diagnostics. The research, conducted at Lille University Hospital in France, describes an innovative method for analyzing multiple myeloma (MM) using Bionano's OGM technology, potentially overcoming longstanding challenges in the field.\nKey findings from the study showcase OGM's ability to effectively analyze MM samples with as few as 0.5 million CD138-positive cells, half the typical requirement. The technology demonstrated 93% concordance with traditional FISH methods while uncovering 22 additional genetic variants. This breakthrough could streamline MM analysis, improve prognostic risk evaluation, and potentially expand the adoption of OGM in hematologic malignancy research. The positive implications for Bionano's technology in addressing unmet medical needs in blood cancer research appear to be driving investor enthusiasm in pre-market trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117867412","isCrawlerRequest":true}